Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:47 PM
Ignite Modification Date:
2025-12-24 @ 11:47 PM
NCT ID:
NCT06242951
Eligibility Criteria:
Inclusion Criteria:
* Aged 7-17 years old
* Referred to the paediatric cardiopulmonary exercise test (CPET) laboratory of Montpellier University Hospital, France
* Have completed a CPET
* For cystic fibrosis group:
* To be followed up in the cystic fibrosis center of Montpellier University
* To be referred to our pediatrician CPET laboratory in 2019, or between July and December 2018 if they have not passed a CPET in 201
• For control group:
* To be referred for non-severe functional symptoms linked to exercise (murmur, palpitation or dyspnea) or for medical sports certificate.
* Having a completely normal check-up, including physical examination, electrocardiogram, echocardiography and spirometry
Exclusion Criteria:
* Patients \< 7 ou \> 17 years old
* Absolute contraindication for CPET : fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction, and children with mental impairment leading to inability to cooperate
* Parents refuse the use of medical data
* For control group : children with any chronic disease, medical condition (cardiac, neurologic, respiratory, muscular, or renal), medical treatment, requiring any further specialized medical consultation or with any finding at clinical and paraclinical examination (electrocardiogram, echocardiography)
Sex:
ALL
Minimum Age:
7 Years
Maximum Age:
17 Years
Study:
NCT06242951
Study Brief:
Protocol Section:
NCT06242951